Sr. Territory Business Manager
Posted on: 17 Sep 2021
Denver, CO
Job Description
Job Description
The Sr. Territory Business Manager is responsible for developing and executing on sales plans for their assigned territory.
In this role, you will convey complex clinical and reimbursement information to customers and key stakeholders regarding Biogen products. You must be able to utilize exemplary interpersonal skills and directed probing to uncover and address the customer's educational needs. This position works closely with cross functional peers to help ensure customers are appropriately educated about available Biogen support services, as needed.
Qualifications
5+ years B2B and/or pharma, specialty, hospital, med device/capital equipment, and/or biotech sales required. A breadth of experiences across these disciplines is highly desirable.
Proven track record of success as demonstrated by consistent high ranking over 3+ years, achievement awards, etc.
Proven ability to drive results in a challenging and ambiguous market; launch, business development and co-promotion experiences are an advantage
Documented experience excelling in a collaborative team setting
Customer and patient focused and able to uncover obstacles, and strategically drive for results with limited direction and in ambiguity
Must have the desire and capabilities to help us achieve new levels of success as we look to the future
Driving is an essential duty of this job; candidates must have a valid driver’s license to be considered
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
